SG154333A1 - The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases - Google Patents

The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases

Info

Publication number
SG154333A1
SG154333A1 SG200608456-0A SG2006084560A SG154333A1 SG 154333 A1 SG154333 A1 SG 154333A1 SG 2006084560 A SG2006084560 A SG 2006084560A SG 154333 A1 SG154333 A1 SG 154333A1
Authority
SG
Singapore
Prior art keywords
preparations containing
associated diseases
treating hyperlipidemia
combination preparations
substituted
Prior art date
Application number
SG200608456-0A
Other languages
English (en)
Inventor
David Grenville Holmes
Thomas Edward Hughes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG154333A1 publication Critical patent/SG154333A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200608456-0A 2002-06-03 2003-06-02 The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases SG154333A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38522002P 2002-06-03 2002-06-03

Publications (1)

Publication Number Publication Date
SG154333A1 true SG154333A1 (en) 2009-08-28

Family

ID=29712145

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200608456-0A SG154333A1 (en) 2002-06-03 2003-06-02 The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases

Country Status (26)

Country Link
US (2) US20050176806A1 (pt)
EP (1) EP1513519B1 (pt)
JP (2) JP2005532338A (pt)
KR (1) KR20050012771A (pt)
CN (2) CN101273987A (pt)
AT (1) ATE422884T1 (pt)
AU (2) AU2003245903B2 (pt)
BR (1) BR0311535A (pt)
CA (1) CA2487297C (pt)
CY (1) CY1112800T1 (pt)
DE (1) DE60326232D1 (pt)
DK (1) DK1513519T3 (pt)
EC (1) ECSP045469A (pt)
ES (1) ES2321600T3 (pt)
HK (1) HK1074794A1 (pt)
IL (1) IL165181A (pt)
MX (1) MXPA04012149A (pt)
NO (1) NO333585B1 (pt)
NZ (1) NZ536832A (pt)
PL (1) PL210408B1 (pt)
PT (1) PT1513519E (pt)
RU (1) RU2362555C2 (pt)
SG (1) SG154333A1 (pt)
SI (1) SI1513519T1 (pt)
WO (1) WO2003101448A1 (pt)
ZA (1) ZA200409136B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101273987A (zh) * 2002-06-03 2008-10-01 诺瓦提斯公司 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
SI3366283T1 (sl) 2004-01-20 2021-12-31 Novartis Ag Formulacija za neposredno stiskanje in postopek
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2006083214A1 (en) * 2005-02-02 2006-08-10 Astrazeneca Ab Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor
WO2006116157A2 (en) 2005-04-22 2006-11-02 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-iv inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
WO2008097535A2 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
EP2556056A1 (en) 2010-04-06 2013-02-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EA021236B1 (ru) * 2012-10-03 2015-05-29 Дафот Энтерпраизес Лимитед Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
JP2018507914A (ja) 2015-03-09 2018-03-22 インテクリン・セラピューティクス・インコーポレイテッド 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
BR112019020485A2 (pt) 2017-04-03 2020-05-12 Coherus Biosciences, Inc. Agonista ppary para tratamento de paralisia supranuclear progressiva
JP2022525888A (ja) * 2019-03-22 2022-05-20 ラッシュ・ユニバーシティ・メディカル・センター リソソーム蓄積症のための、経鼻遺伝子送達と経口の桂皮酸、オレアミド、またはゲムフィブロジルとの組合せ

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187052A1 (fr) * 1984-10-31 1986-07-09 S.A. PANMEDICA Société dite: Nouveaux dérivés de l'adamantanamine, leurs procédés de préparation et médicaments les contenant
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO2000034241A1 (en) * 1998-12-10 2000-06-15 Novartis Ag N-substituted 2-cyanopyrrolidines
EP1125922A1 (en) * 1998-11-02 2001-08-22 Welfide Corporation Pyrrolidine compounds and medicinal utilization thereof
WO2003038123A2 (en) * 2001-10-31 2003-05-08 Novartis Ag Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
EP2574336A1 (en) * 1998-02-02 2013-04-03 Trustees Of Tufts College Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
DE19828114A1 (de) * 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
JP4232332B2 (ja) * 1999-11-10 2009-03-04 末藏 岩田 タンク付電動床磨機用ブラシ台
DE122008000018I1 (de) * 2000-01-21 2008-08-14 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
AR039090A1 (es) * 2002-03-22 2005-02-09 Novartis Ag Combinacion de compuestos organicos
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
CN101273987A (zh) * 2002-06-03 2008-10-01 诺瓦提斯公司 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
US7935723B2 (en) * 2004-06-04 2011-05-03 Novartis Pharma Ag Use of organic compounds
AU2006292377B2 (en) * 2005-09-20 2011-03-03 Emisphere Technologies, Inc. Use of a DPP-IV inhibitor to reduce hypoglycemic events

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187052A1 (fr) * 1984-10-31 1986-07-09 S.A. PANMEDICA Société dite: Nouveaux dérivés de l'adamantanamine, leurs procédés de préparation et médicaments les contenant
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP1125922A1 (en) * 1998-11-02 2001-08-22 Welfide Corporation Pyrrolidine compounds and medicinal utilization thereof
WO2000034241A1 (en) * 1998-12-10 2000-06-15 Novartis Ag N-substituted 2-cyanopyrrolidines
US6166063A (en) * 1998-12-10 2000-12-26 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO2003038123A2 (en) * 2001-10-31 2003-05-08 Novartis Ag Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene

Also Published As

Publication number Publication date
US20120014907A1 (en) 2012-01-19
EP1513519A1 (en) 2005-03-16
MXPA04012149A (es) 2005-04-19
CN100402026C (zh) 2008-07-16
WO2003101448A1 (en) 2003-12-11
HK1074794A1 (en) 2005-11-25
ATE422884T1 (de) 2009-03-15
ECSP045469A (es) 2005-01-28
AU2003245903A1 (en) 2003-12-19
DK1513519T3 (da) 2009-06-02
NO333585B1 (no) 2013-07-15
US20050176806A1 (en) 2005-08-11
PT1513519E (pt) 2009-05-06
AU2006246483B9 (en) 2010-08-12
AU2003245903B2 (en) 2006-11-30
NO20045452L (no) 2005-03-01
BR0311535A (pt) 2005-02-22
CY1112800T1 (el) 2016-02-10
AU2006246483A1 (en) 2006-12-21
PL210408B1 (pl) 2012-01-31
KR20050012771A (ko) 2005-02-02
RU2004139029A (ru) 2005-08-27
SI1513519T1 (sl) 2009-06-30
RU2362555C2 (ru) 2009-07-27
DE60326232D1 (de) 2009-04-02
ZA200409136B (en) 2005-07-27
CN101273987A (zh) 2008-10-01
NZ536832A (en) 2006-11-30
CA2487297A1 (en) 2003-12-11
IL165181A (en) 2010-06-16
IL165181A0 (en) 2005-12-18
EP1513519B1 (en) 2009-02-18
JP2010155866A (ja) 2010-07-15
ES2321600T3 (es) 2009-06-09
JP2005532338A (ja) 2005-10-27
CA2487297C (en) 2011-08-09
PL374016A1 (en) 2005-09-19
CN1658867A (zh) 2005-08-24
AU2006246483B2 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
SG154333A1 (en) The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
SE0104340D0 (sv) New compounds
MXPA04000328A (es) Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
TW200512195A (en) Benzamide 2-hydroxy-3-diaminoalkanes
ES2165969T3 (es) Compuestos nitrogenados aromaticos condensados 5,5 aril-sustituidos como agentes antiinflamatorios.
ATE448199T1 (de) Verbindungen mit taxol-verstärkender wirkung
MXPA02012034A (es) Derivados de tiofeno utiles como agentes anticancerosos.
NO20050573L (no) 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
TW200505828A (en) Substituted ureas and carbamates useful in the treatment of alzheimer's disease
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
AR002018A1 (es) Derivado de benzotiepina opticamente activo; metodo para producirlo; compuesto opticamente activo de uso en dicho metodo; promotor deosteogenesis, agente para prevenir o tratar enfermedades del hueso, promotor para el tratamiento de la fractura de hueso, metodo de tratamiento y
RU94038256A (ru) Производные пиразолопиримидина, способ их получения, фармацевтические композиции на их основе
SE0102440D0 (sv) New compound
HUT55034A (en) Process for producing peptides with hemoregulating effect and pharmaceutical compositions comprising such compounds as active ingredient
MXPA05013607A (es) Candidatos de farmaco farmaceuticos mejorados y metodos para preparar los mismos.
HK1075894A1 (en) Prucalopride-n-oxide
MXPA04000485A (es) Uso de acidos aril o heteroaril hidroxamicos de sulfonilo y derivados de los mismos como inhibidores de agrecanasa.
DE69904025D1 (de) Kondensierte Pyrimidinderivate und diese enthaltende pharmazeutische Zubereitungen
TW200517367A (en) Improved pharmaceutical drug candidates and methods for preparation thereof
ATE301997T1 (de) Antivirale therapie
DK0706796T3 (da) Dopamingenoptagelsesinhibitorer til behandling af parkinsonisme
LV12459A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai